As assessed by serum anti-SCB-2019 IgG antibody titers;Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs);Incidence of solicited adverse events (AEs) after vaccination;Incidence of unsolicited AEs after vaccination;Mean change from Baseline in safety laboratory measures (include hematology, coagulation panel, and serum chemistry)

As assessed by serum anti-SCB-2019 IgG antibody titers;Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs);Incidence of solicited adverse events (AEs) after vaccination;Incidence of unsolicited AEs after vaccination;Mean change from Baseline in safety laboratory measures (include hematology, coagulation panel, and serum chemistry)

Incidence of unsolicited AEs after vaccination;Immunogenicity(Anti-SCB-2019 Antibody Titers);Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs);Incidence of solicited adverse events (AEs) after vaccination

Incidence of unsolicited AEs after vaccination;Immunogenicity(Anti-SCB-2019 Antibody Titers);Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs);Incidence of solicited adverse events (AEs) after vaccination